TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both man and woman who is over 19 years old~* Patient with dyslipidemia and hypertension~* Written informed consent~Exclusion Criteria:~* Triglyceride ≥ 400 mg/dL at screening~* Hypertensive patients who need antihypertensive medication except Amlodipine, β-blockers, RAS inhibitors~* sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg~* A history of rhabdomyolysis, myopathy~* Patient with hypersensitivity to Statin or Amlodipine~* Patients undergoing eGFR \<30 mL/min/1.73 m2 (MDRD) at screening~* AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper limit of normal range) or active liver disease~* Creatine kinase (CK) level ≥ 5x ULN (upper limit of normal range)~* Contraindications stated in the Label of Rosuampin or Caduet~* Those participating in other clinical trials for investigational products at screening~* Patients deemed to be ineligible to participate in the trial by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuampin 10/5mg (Type: EXPERIMENTAL): Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
- Rosuampin 20/5mg (Type: EXPERIMENTAL): Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
- Amlodipine/Atorvastatin 5/20mg (Type: ACTIVE_COMPARATOR): Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female participants ≥18 years of age.~2. History of ASCVD (coronary heart disease \[CHD\], cardiovascular disease \[CVD\], or peripheral arterial disease \[PAD\]).~3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).~4. Fasting triglyceride \<4.52 mmol/L (\<400 mg/dL) at screening.~5. Participants on statins should be receiving a maximally tolerated dose.~6. Participants not receiving statins must have documented evidence of intolerance to all doses of at least 2 different statins.~7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation.~Exclusion Criteria:~1. New York Heart Association (NYHA) class IV heart failure.~2. Uncontrolled cardiac arrhythmia~3. Uncontrolled severe hypertension~4. Active liver disease~5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least 2 methods of highly effective contraception (failure rate less than 1% per year) (for example, combined oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:~   1. Women \>2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age.~  2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.~  3. Women who are surgically sterilized at least 3 months prior to enrollment.~6. Males who are unwilling to use an acceptable method of birth control during the entire study period (such as condom with spermicide).~7. Treatment with other investigational products or devices within 30 days or 5 half-lives of the screening visit, whichever is longer.~8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inclisiran (Type: EXPERIMENTAL): Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
- Saline Solution (Type: PLACEBO_COMPARATOR): Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Without fever for 72 hours prior to vaccination~Exclusion Criteria:~* Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine~* Known or suspected to be immunocompromised~* Functional or anatomic asplenia~* History of autoimmune disease~* Evidence of dementia or cognitive impairment~* Use of any immunosuppressive therapy~* Received a licensed non-live vaccine administered within the 14 days prior to receipt of study vaccine or scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine~* Received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine~* Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine~* Received a blood transfusion or blood products within the 6 months before receipt of study vaccine or scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine~* History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease~* Received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
- PNEUMOVAX® 23 (Type: ACTIVE_COMPARATOR): Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
- PREVNAR 13® (Type: ACTIVE_COMPARATOR): Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine and CRP in Atrial Fibrillation and AF Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices. Diagnosis of AF will be made based on the 12 -lead surface ECG.~* Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology laboratory for the procedure in sinus rhythm..~* Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in the electrophysiology laboratory in atrial fibrillation .~Exclusion Criteria:~1. Abnormal liver function with elevated enzymes\> 1.5 times the normal.~2. Abnormal kidney function with glomerular filtration rate \< 50 ml/min~3. Increased levels of creatine kinase or known myopathy~4. Neutropenia~5. Known GI disorders~6. Women of childbearing age who have not had surgical sterilization and are not using oral contraceptives, or who's spouse has not had surgical sterilization will be excluded due to the length of the trial and the possibility that they could become pregnant after entry.~7. Pregnant and lactating women~8. Lactose intolerance~9. Known sensitivity, allergy, or contraindication to colchicine use

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic atrial fibrillation, colchicine (Type: ACTIVE_COMPARATOR): Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
- Chronic atrial fibrillation, placebo (Type: PLACEBO_COMPARATOR): Matching placebo. Subjects not undergoing ablation.
- Pre-ablation, sinus rhythm, colchicine (Type: ACTIVE_COMPARATOR): Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
- Pre-ablation, sinus rhythm, placebo (Type: PLACEBO_COMPARATOR): Matching placebo. Subjects undergoing ablation.
- Pre-ablation, AF, colchicine (Type: ACTIVE_COMPARATOR): Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
- Pre-ablation, AF, placebo (Type: PLACEBO_COMPARATOR): Matching placebo. Subjects undergoing ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\> 1 and a PGA \<=2) with compatible histology~* females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception~Exclusion Criteria:~* subjects with relapsing UC who were in relapse for \> 6 weeks prior to baseline~* subjects who relapsed on maintenace therapy with doses of mesalazine =\> 2g/day~* subjects who had unsuccessfully treated their current relapse with steroids or a mesalazine dose of \> 2g/day~* subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or a stool culture positive for enteric pathogens~* subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit~* subjects with hypersensitivity to salicylates and subjects with moderate/severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age \>= 40 years;~2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;~3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF~4. Dlco (corrected for Hb): 30%-79% predicted of normal; 5.FVC\>= 50% predicted of normal~Exclusion criteria:~1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \> 1.5 x Upper Limit of Normal (ULN)~2. Bilirubin \> 1.5 x ULN;~3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC \< 0.7);~4. Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);~5. Myocardial infarction within 6 months;~6. Unstable angina within 1 month;~7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);~8. Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and transient ischemic attacks) within 12 months;~9. International normalised ratio (INR) \> 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \> 50% of institutional ULN);~10. N-ACetyl Cystein, prednisone \> 15mg/day or equivalent received within 2 weeks of visit 1;~11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1;

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): patient receives capsules identical to those containing active drug
- BIBF 1120 (Type: EXPERIMENTAL): patient receives capsules containing BIBF 1120 twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (\< 1% FVIII)~* 30-45 years of age~* Previously treated subject (\> 100 Exposure days to any FVIII)~* On-demand therapy with any FVIII~Exclusion Criteria:~* No history of inhibitor~* No planned elective orthopedic surgery during the study duration (13 months)~* No severe concomitant disease~* No history of anaphylactic or other severe reaction to previous FVIII treatment

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- rFVIII-FS (octocog-alfa), (Kogenate FS) (Type: EXPERIMENTAL): On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 years or older.~* Laboratory-confirmed hereditary angioedema type I or II.~* Less than two hereditary angioedema attacks per month in the last three months.~* Body weight of 50.0 kg to 110.0 kg.~Exclusion Criteria:~* Receiving prophylactic C1-esterase inhibitor therapy.~* Received C1-esterase inhibitor, ecallantide, icatibant or any blood products for the prevention or treatment of hereditary angioedema within 7 days before the screening visit.~* Intends to use recombinant C1-esterase inhibitor or fresh frozen plasma for the acute treatment of hereditary angioedema during the study.~* Received androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 30 days before the screening visit.~* Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing products) within 3 months prior to the screening visit.~* Known or suspected hypersensitivity to the study product, or to any excipients of the study product.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low, then medium, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Medium, then low, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Medium, then high, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Low, then high, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- High, then low, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- High, then medium, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated CD20-positive DLBCL confirmed by histopathology or cytology.~* 18 years to 75 years; Male or female patients.~* International Prognostic Index (IPI) score of 0 to 2.~* Signed an informed consent.~* At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0 cm in the long axis.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* More than 6 months life expectancy.~Exclusion Criteria:~* Participation in another interventional clinical trial in the past 3 months.~* Known allergic reactions against monoclonal antibody or rituximab.~* Contraindication to any component of CHOP regimen.~* Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody within 3 month.~* History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).~* Primary central nervous system (CNS) lymphoma, secondary CNS involvement, primary testicular lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI301 (Type: EXPERIMENTAL): IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
- Rituximab (Type: ACTIVE_COMPARATOR): Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being diagnosed with a Disease of the Neuromuscular junction, according to International Classification of Diseases 10.~* Be aged between 3 and 18 years.~Exclusion Criteria:~* Being unable to perform spirometry, for physical or psychological difficulties.~* Be involved in another program Respiratory Physiotherapy.~* Present some kind of associated pathology (such as broken ribs, state epilepticus ...) in which it is contraindicated any maneuvers of the respiratory therapy protocol designed.~* If researchers are informed of the existence of a serious illness of the father / mother / tutor that preclude to carrying out the program of respiratory Physiotherapy at home.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY (Type: EXPERIMENTAL): Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
- GROUP RECEIVING THEIR USUAL THERAPIES (Type: EXPERIMENTAL): This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete